Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sampling probability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Sampling probability. Displaying page 1 of 1.
    EudraCT Number: 2014-004108-31 Sponsor Protocol Number: RHB-104-03 Start Date*: 2015-08-27
    Sponsor Name:RedHill Biopharma Ltd.
    Full Title: A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately Active Cr...
    Medical condition: Moderately Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000196-24 Sponsor Protocol Number: 402-C-1504 Start Date*: 2016-07-04
    Sponsor Name:Reata Pharmaceuticals, Inc.
    Full Title: A STUDY OF THE EFFICACY AND SAFETY OF BARDOXOLONE METHYL IN PATIENTS WITH CONNECTIVE TISSUE DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION
    Medical condition: Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (WHO Group I CTD-PAH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002053-69 Sponsor Protocol Number: 3068A1-301-WW Start Date*: 2002-08-13
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: FRACTURE INCIDENCE REDUCTION AND SAFETY OF TSE-424 (BAZEDOXIFENE ACETATE) COMPARED TO PLACEBO AND RALOXIFENE IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN
    Medical condition: Reduction of new vertebral fractures in osteoporotic postmenopausal women- Osteoporosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2022-001627-32 Sponsor Protocol Number: CVAY736Q12301 Start Date*: 2023-03-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or r...
    Medical condition: immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-007742-35 Sponsor Protocol Number: FINA-003 Start Date*: 2008-10-01
    Sponsor Name:MerLion Pharmaceuticals GmbH
    Full Title: A double-blind, double-dummy, prospective, randomized multiple-site study of oral Finafloxacin 300 mg b.i.d. versus oral Ciprofloxacin 250 mg b.i.d. in patients with lower uncomplicated UTI (uUTI) ...
    Medical condition: Lower uncomplicated Urinary Tract Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046571 Urinary tract infection LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002131-34 Sponsor Protocol Number: GS-US-357-1394 Start Date*: 2015-05-07
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Men and women, ages 18 through 75 years, with a diagnosis of idiopathic PAH, heritable PAH or PAH associated with connective tissue disease (PAH-CTD), congenital heart defects (repaired), drug and ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005684-32 Sponsor Protocol Number: Start Date*: 2015-12-30
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: [18F] DIHYDRO-TESTOSTERONE PET IMAGING IN PATIENTS WITH PROGRESSIVE PROSTATE CANCER
    Medical condition: Progressive Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004084-10 Sponsor Protocol Number: T001018N Start Date*: 2022-05-16
    Sponsor Name:Flemisch Fund for Scientific Research - Fonds voor Wetenschappelijk Onderzoek
    Full Title: Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment; a pragmatic randomised controlled trial
    Medical condition: Rifampicin resistant (RR-TB) and drug resistant (DR-TB) tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10049031 Genotype drug resistance test PT
    20.1 10018065 - General disorders and administration site conditions 10048723 Multiple-drug resistance PT
    20.0 10018065 - General disorders and administration site conditions 10059866 Drug resistance PT
    20.0 100000004862 10004052 Bacterial resistance LLT
    20.0 100000004862 10038637 Resistance bacterial LLT
    20.1 100000004862 10028152 Multi-antibiotic resistance LLT
    20.0 10022891 - Investigations 10070974 Antibiotic resistance test LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2020-000986-17 Sponsor Protocol Number: ALZ-801-201ADBM Start Date*: 2020-09-11
    Sponsor Name:Alzheon Inc.
    Full Title: A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4)
    Medical condition: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4, APOE3/4) and at the Early stage of disease, ages 50-80 years
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012025-11 Sponsor Protocol Number: 01373 Start Date*: 2010-01-26
    Sponsor Name:D-Pharm Ltd.
    Full Title: A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus...
    Medical condition: Acute Ischemic Stroke Stroke is the most common neurologic disorder and is the third leading cause of death in developed countries, after myocardial infarction and cancer. Stroke is the second l...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) PT (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) AT (Prematurely Ended) SK (Completed) IT (Prematurely Ended) NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002856-37 Sponsor Protocol Number: BV100-006 Start Date*: 2023-01-30
    Sponsor Name:BioVersys SAS
    Full Title: A multicenter, open-label, randomized, active-controlled, Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B versus best available t...
    Medical condition: ventilator-associated bacterial pneumonia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10081414 Ventilator associated bacterial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000977-62 Sponsor Protocol Number: 012418QM Start Date*: 2018-09-28
    Sponsor Name:Queen Mary University of London
    Full Title: BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
    Medical condition: Triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000814-73 Sponsor Protocol Number: RG_14-072 Start Date*: 2016-07-15
    Sponsor Name:University of Birmingham
    Full Title: National Lung Matrix Trial: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer
    Medical condition: Metastatic or locally advanced non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 11:15:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA